Shares of Inovio climbed in trading after the company announced its DNA vaccine candidate for Covid-19 induced a robust T-cell response against multiple variants of the SARS-CoV-2 virus.
The first study to directly compare immune reactions between Pfizer’s and AstraZeneca’s Covid-19 vaccines found strong and broadly similar antibody responses in over-80-year-olds after a first dose of either shot, scientists said on April 14.
Paris-based Sanofi bought Cambridge, Massachusetts-based Tidal Therapeutics in a deal totaling $470 million.
While a failed ebola drug helped treat hospitalized Covid-19 patients, the common cold virus could become key in treating advanced unresectable cancers.
Chimeric antigen receptor (CAR-T) therapy is one of the biggest cancer therapy breakthroughs of our time, but as with any precise science, there is still some fine-tuning to be done to overcome safety risks, limited payload capacity and the prohibitive cost of manufacturing.
A critical component of the immune system known as T cells that respond to fight infection from the original version of the novel coronavirus appear to also protect against three of the most concerning new virus variants, according to a U.S. laboratory study released on March 30.
FUJIFILM selected the town of Holly Springs, North Carolina, as the company’s spot to build the largest cell culture biopharmaceutical production facility in North America.
Along with inducing antibodies for immediate defense, mRNA vaccines against Covid-19 also stimulate the lymph nodes to generate immune cells that provide protection over the long term, a new study confirms.
Takeda Pharmaceutical is advancing the Japanese pharma giant’s immune-oncology portfolio through the acquisition of the immunotherapy pioneer Maverick Therapeutics.
AstraZeneca and Amgen’s experimental drug tezepelumab reduced asthma attacks in patients with severe and uncontrolled forms of the respiratory condition in a large study, showing promise for wider use against different triggers.